Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
- PMID: 30717149
- PMCID: PMC6473515
- DOI: 10.3390/tropicalmed4010026
Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Abstract
Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent and fast acting antimalarials; but they have a short half-life and need to be combined with partner drugs with a longer half-life to clear the remaining parasites after a standard 3-day ACT regimen. When introduced, ACTs were highly efficacious and contributed to the steep decrease of malaria over the last decades. However, parasites with decreased susceptibility to artemisinins have emerged in the Greater Mekong Subregion (GMS), followed by ACTs' failure, due to both decreased susceptibility to artemisinin and partner drug resistance. Therefore, there is an urgent need to strengthen and expand current resistance surveillance systems beyond the GMS to track the emergence or spread of artemisinin resistance. Great attention has been paid to the spread of artemisinin resistance over the last five years, since molecular markers of decreased susceptibility to artemisinin in the GMS have been discovered. However, resistance to partner drugs is critical, as ACTs can still be effective against parasites with decreased susceptibility to artemisinins, when the latter are combined with a highly efficacious partner drug. This review outlines the different mechanisms of resistance and molecular markers associated with resistance to partner drugs for the currently used ACTs. Strategies to improve surveillance and potential solutions to extend the useful therapeutic lifespan of the currently available malaria medicines are proposed.
Keywords: antimalarial; artemisinin; drug; molecular marker; partner drug; resistance; surveillance.
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite.Curr Opin Pharmacol. 2018 Oct;42:71-80. doi: 10.1016/j.coph.2018.07.010. Epub 2018 Aug 22. Curr Opin Pharmacol. 2018. PMID: 30142480 Review.
-
Geographic expansion of artemisinin resistance.J Travel Med. 2019 Jun 1;26(4):taz030. doi: 10.1093/jtm/taz030. J Travel Med. 2019. PMID: 30995310 Review.
-
The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.FEMS Microbiol Rev. 2017 Jan;41(1):34-48. doi: 10.1093/femsre/fuw037. Epub 2016 Sep 8. FEMS Microbiol Rev. 2017. PMID: 27613271 Free PMC article. Review.
-
How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.Trends Parasitol. 2011 Feb;27(2):67-72. doi: 10.1016/j.pt.2010.09.005. Trends Parasitol. 2011. PMID: 20971040
-
Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa.Malar J. 2021 Oct 13;20(1):401. doi: 10.1186/s12936-021-03942-5. Malar J. 2021. PMID: 34645475 Free PMC article.
Cited by
-
Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives.Trop Med Infect Dis. 2024 Sep 20;9(9):223. doi: 10.3390/tropicalmed9090223. Trop Med Infect Dis. 2024. PMID: 39330912 Free PMC article. Review.
-
Risk of selection and timelines for the continued spread of artemisinin and partner drug resistance in Africa.medRxiv [Preprint]. 2024 Aug 28:2024.08.28.24312699. doi: 10.1101/2024.08.28.24312699. medRxiv. 2024. PMID: 39252921 Free PMC article. Preprint.
-
Evaluation of Segmentation, Rotation, and Geographic Delivery Approaches for Deployment of Multiple First-Line Treatment (MFT) to Respond to Antimalarial Drug Resistance in Africa: A Qualitative Study in Seven Sub-Sahara Countries.Trop Med Infect Dis. 2024 Apr 23;9(5):93. doi: 10.3390/tropicalmed9050093. Trop Med Infect Dis. 2024. PMID: 38787026 Free PMC article.
-
Study of marine microorganism metabolites: new resources for bioactive natural products.Front Microbiol. 2024 Jan 8;14:1285902. doi: 10.3389/fmicb.2023.1285902. eCollection 2023. Front Microbiol. 2024. PMID: 38260902 Free PMC article. Review.
-
State-of-the-art Review on the Antiparasitic Activity of Benzimidazolebased Derivatives: Facing Malaria, Leishmaniasis, and Trypanosomiasis.Curr Med Chem. 2024;31(15):1955-1982. doi: 10.2174/0929867331666230915093928. Curr Med Chem. 2024. PMID: 37718524 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources